Atea Pharmaceuticals (AVIR) announced the appointment of Howard Berman, Ph.D. to its Board of Directors. Dr. Berman will serve as a non-voting observer to the Board through Atea’s 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. The Company is adding Dr. Berman to the Board as part of its entry into an agreement with Bradley Radoff and Michael Torok. In connection with the Agreement, the Radoff-JEC Group has withdrawn its slate of nominated director candidates and has agreed to vote all of the shares it collectively owns in favor of each of Atea’s Board nominees at the 2025 Annual Meeting. The Company also announced that Franklin Berger has informed the Company of his intention not to stand for reelection at Atea’s 2027 Annual Meeting of Stockholders. Berman, Ph.D., is the Founder, Executive Chairman and former CEO of Coya Therapeutics (COYA).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
- Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
- Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
- Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board
- Atea Pharmaceuticals issues statement regarding director nominations